You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDocetaxel
Accession NumberDB01248  (APRD00932)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionDocetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.
Structure
Thumb
Synonyms
Docetaxel anhydrous
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
TXL
External Identifiers
  • RP-6976
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DocefrezkitSun Pharma Global FZE2011-05-03Not applicableUs
Docetaxelinjection, solution, concentrate80 mg/4mLintravenousWinthrop U.S.2010-10-21Not applicableUs
Docetaxelinjection, solution, concentrate20 mg/2mLintravenousPfizer Laboratories Div Pfizer Inc2014-06-23Not applicableUs
Docetaxelinjection, solution, concentrate20 mg/mLintravenousActavis Pharma, Inc.2015-10-13Not applicableUs
Docetaxelinjection, solution, concentrate20 mg/mLintravenousAccord Healthcare Inc.2012-07-01Not applicableUs
DocetaxelkitAccord Healthcare Inc.2011-06-30Not applicableUs
Docetaxelinjection, solution10 mg/mLintravenousSandoz Inc2011-06-29Not applicableUs
Docetaxelinjection, solution20 mg/mLintravenousNorthstar Rx LLC2016-01-01Not applicableUs
Docetaxelinjection, solution, concentrate80 mg/8mLintravenousPfizer Laboratories Div Pfizer Inc2014-06-23Not applicableUs
Docetaxelinjection, solution, concentrate20 mg/mLintravenousAccord Healthcare Inc.2013-05-15Not applicableUs
Docetaxelinjection, solution, concentrate20 mg/mLintravenousActavis Pharma, Inc.2014-09-01Not applicableUs
Docetaxelinjection, solution10 mg/mLintravenousSandoz Inc2015-07-22Not applicableUs
Docetaxelinjection, solution10 mg/mLintravenousHospira, Inc.2011-03-08Not applicableUs
Docetaxelinjection, solution80 mg/4mLintravenousNorthstar Rx LLC2016-01-01Not applicableUs
Docetaxelinjection, solution, concentrate200 mg/20mLintravenousPfizer Laboratories Div Pfizer Inc2014-06-23Not applicableUs
Docetaxelinjection, solution20 mg/mLintravenousMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2011-06-08Not applicableUs
Docetaxelinjection, solution, concentrate20 mg/mLintravenousActavis Pharma, Inc.2014-09-01Not applicableUs
Docetaxelinjection, solution, concentrate20 mg/mLintravenousWinthrop U.S.2010-10-21Not applicableUs
DocetaxelkitAccord Healthcare Inc.2011-06-30Not applicableUs
Docetaxelinjection, solution20 mg/mLintravenousMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2011-06-08Not applicableUs
Docetaxelinjection, solution, concentrate20 mg/mLintravenousActavis Pharma, Inc.2014-09-01Not applicableUs
Docetaxel for Injectionsolution10.0 mgintravenousHospira Healthcare Corporation2011-03-01Not applicableCanada
Docetaxel Injectionsolution80 mgintravenousTeva Canada Limited2014-03-28Not applicableCanada
Docetaxel Injectionsolution20 mgintravenousAccord Healthcare Inc2015-02-27Not applicableCanada
Docetaxel Injectionsolution10 mgintravenousSandoz Canada Incorporated2016-06-02Not applicableCanada
Docetaxel Injectionsolution20 mgintravenousTeva Canada Limited2014-03-28Not applicableCanada
Docetaxel Non-alcohol Formulainjection20 mg/mLintravenousEagle Pharmaceuticals, Inc.2016-01-15Not applicableUs
PMS-docetaxelsolution; kit20 mgintravenousPharmascience IncNot applicableNot applicableCanada
PMS-docetaxelsolution; kit80 mgintravenousPharmascience IncNot applicableNot applicableCanada
Taxoteresolution20 mgintravenousSanofi Aventis Canada Inc1995-12-31Not applicableCanada
Taxotereinjection, solution, concentrate80 mg/4mLintravenousSanofi Aventis U.S. Llc2010-08-02Not applicableUs
Taxoteresolution80 mgintravenousSanofi Aventis Canada Inc1995-12-31Not applicableCanada
Taxotereinjection, solution, concentrate20 mg/mLintravenousSanofi Aventis U.S. Llc2010-08-02Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Docetaxelinjection, solution, concentrate20 mg/mLintravenousTeva Parenteral Medicines, Inc.2015-12-31Not applicableUs
Docetaxelinjection, solution20 mg/mLintravenousDr. Reddy's Laboratories Inc.2014-11-10Not applicableUs
Docetaxelinjection, solution, concentrate80 mg/4mLintravenousTeva Parenteral Medicines, Inc.2015-12-31Not applicableUs
Docetaxelsolution20 mg/mLintravenousSagent Pharmaceuticals2013-07-01Not applicableUs
Docetaxelinjection, solution20 mg/mLintravenousDr. Reddy's Laboratories Inc.2014-11-10Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Docetaxel Teva PharmaConcentrate and solvent for solution for infusion20 mgIntravenous useTeva Pharma B.V.2011-01-21Not applicableEu
Docetaxel Teva PharmaConcentrate and solvent for solution for infusion80 mgIntravenous useTeva Pharma B.V.2011-01-21Not applicableEu
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Docetaxel trihydrate
148408-66-6
Thumb
  • InChI Key: XCDIRYDKECHIPE-QHEQPUDQSA-N
  • Monoisotopic Mass: 861.378299444
  • Average Mass: 861.935
DBSALT001786
Categories
UNII699121PHCA
CAS number114977-28-5
WeightAverage: 807.8792
Monoisotopic: 807.346605409
Chemical FormulaC43H53NO14
InChI KeyInChIKey=ZDZOTLJHXYCWBA-VCVYQWHSSA-N
InChI
InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1
IUPAC Name
(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1,9,12-trihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0³,¹⁰.0⁴,⁷]heptadec-13-en-2-yl benzoate
SMILES
[H][C@@]12C[[email protected]](O)[C@@]3(C)C(=O)[[email protected]](O)C4=C(C)[[email protected]](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[[email protected]](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as taxanes and derivatives. These are diterpenoids with a structure based either on the taxane skeleton, or a derivative thereof. In term of phytochemistry, several derivatives of the taxane skeleton exist
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassPrenol lipids
Sub ClassDiterpenoids
Direct ParentTaxanes and derivatives
Alternative Parents
Substituents
  • Taxane diterpenoid
  • Phenylpropylamine
  • Benzoate ester
  • Tricarboxylic acid or derivatives
  • Benzylether
  • Benzoic acid or derivatives
  • Benzoyl
  • Fatty acid ester
  • Fatty acyl
  • Benzenoid
  • Monosaccharide
  • Monocyclic benzene moiety
  • Acetate salt
  • Tertiary alcohol
  • Cyclic alcohol
  • Secondary alcohol
  • Polyol
  • Oxetane
  • Ketone
  • Carboxylic acid ester
  • Oxacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. It is also used in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Furthermore, docetaxel has uses in the treatment of gastric adenocarinoma and head and neck cancer.
PharmacodynamicsDocetaxel is a taxoid antineoplastic agent. It promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, docetaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.
Mechanism of actionDocetaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, docetaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, docetaxel binds to the β-subunit of tubulin. Tubulin is the "building block" of mictotubules, and the binding of docetaxel locks these building blocks in place. The resulting microtubule/docetaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that docetaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function.
Related Articles
AbsorptionThe pharmacokinetic profile is consistent with a three-compartment model. The area under the curve (AUC) was dose proportional following doses of 70 mg/m2 to 115 mg/m2 with infusion times of 1 to 2 hours.
Volume of distribution

The initial rapid decline represents distribution to the peripheral compartments and the late (terminal) phase is due, in part, to a relatively slow efflux of docetaxel from the peripheral compartment.

  • 113 L
Protein bindingIn vitro studies show that 94% protein bound, mainly to a1-acid glycoprotein, albumin, and lipoproteins. When measured in cancer patients, docetaxel is 97% bound to plasma protein. Dexamethasone does not affect the protein binding of docetaxel.
Metabolism

Hepatic. In vitro drug interaction studies revealed that docetaxel is metabolized by the CYP3A4 isoenzyme (1 major, 3 minor metabolites).

Route of eliminationDocetaxel was eliminated in both the urine and feces following oxidative metabolism of the tert-butyl ester group, but fecal excretion was the main elimination route. Within 7 days, urinary and fecal excretion accounted for approximately 6% and 75% of the administered radioactivity, respectively.
Half lifeDose-dependent. Doses of 70 mg per square meter of body surface area (mg/m 2 ) or higher produce a triphasic elimination profile. With lower doses, assay limitations precluded detection of the terminal elimination phase. The half-life of the alpha, beta, and gamma phase are 4 minutes, 36 minutes, and 11.1 hours, respectively.
Clearance
  • 21 L/h/m2 [Total body clearance, cancer patients after IV administration of 20–115 mg/m2]
ToxicityOral LD50 in rat is >2000 mg/kg. Anticipated complications of overdosage include: bone marrow suppression, peripheral neurotoxicity, and mucositis. In two reports of overdose, one patient received 150 mg/m2 and the other received 200 mg/m2 as 1-hour infusions. Both patients experienced severe neutropenia, mild asthenia, cutaneous reactions, and mild paresthesia, and recovered without incident.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Docetaxel Action PathwayDrug actionSMP00435
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Canalicular multispecific organic anion transporter 1
Gene symbol: ABCC2
UniProt: Q92887
rs12762549 Not AvailableG AlleleLeukopenia, neutropenia18294295
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9743
Blood Brain Barrier-0.9659
Caco-2 permeable-0.8252
P-glycoprotein substrateSubstrate0.8259
P-glycoprotein inhibitor IInhibitor0.644
P-glycoprotein inhibitor IINon-inhibitor0.5139
Renal organic cation transporterNon-inhibitor0.9393
CYP450 2C9 substrateNon-substrate0.816
CYP450 2D6 substrateNon-substrate0.8828
CYP450 3A4 substrateSubstrate0.7119
CYP450 1A2 substrateNon-inhibitor0.8299
CYP450 2C9 inhibitorNon-inhibitor0.8737
CYP450 2D6 inhibitorNon-inhibitor0.8972
CYP450 2C19 inhibitorNon-inhibitor0.8421
CYP450 3A4 inhibitorNon-inhibitor0.7324
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8776
Ames testNon AMES toxic0.8382
CarcinogenicityNon-carcinogens0.9133
BiodegradationNot ready biodegradable0.9934
Rat acute toxicity2.5741 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9907
hERG inhibition (predictor II)Non-inhibitor0.7905
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionintravenous10 mg/mL
Injection, solutionintravenous20 mg/mL
Injection, solutionintravenous80 mg/4mL
Injection, solution, concentrateintravenous20 mg/2mL
Injection, solution, concentrateintravenous200 mg/20mL
Injection, solution, concentrateintravenous80 mg/8mL
Kit
Solutionintravenous20 mg/mL
Solutionintravenous10.0 mg
Solutionintravenous10 mg
Injectionintravenous20 mg/mL
Concentrate and solvent for solution for infusionIntravenous use20 mg
Concentrate and solvent for solution for infusionIntravenous use80 mg
Solution; kitintravenous20 mg
Solution; kitintravenous80 mg
Injection, solution, concentrateintravenous20 mg/mL
Injection, solution, concentrateintravenous80 mg/4mL
Solutionintravenous20 mg
Solutionintravenous80 mg
Prices
Unit descriptionCostUnit
Taxotere 20 mg/0.5 ml vial477.37USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2149055 No2003-01-072013-11-08Canada
CA2150576 No2005-06-212013-11-26Canada
US4814470 No1993-05-142010-05-14Us
US5438072 No1994-05-222014-05-22Us
US8940786 No2013-09-302033-09-30Us
US9308195 No2013-09-302033-09-30Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point232 °CPhysProp
water solubilityInsoluble FDA label
logP2.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0127 mg/mLALOGPS
logP2.59ALOGPS
logP2.92ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)10.96ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area224.45 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity203.9 m3·mol-1ChemAxon
Polarizability82.06 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Nicholas J. Sisti, Charles S. Swindell, “Method for docetaxel synthesis.” U.S. Patent US5688977, issued September, 1991.

US5688977
General ReferencesNot Available
External Links
ATC CodesL01CD02
AHFS Codes
  • 10:00.00
PDB EntriesNot Available
FDA labelDownload (140 KB)
MSDSDownload (100 KB)
Interactions
Drug Interactions
Drug
2-(4-Chlorophenyl)-5-QuinoxalinecarboxamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.
2-HYDROXY-1,4-NAPHTHOQUINONEThe metabolism of Docetaxel can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.
2-mercaptobenzothiazoleThe metabolism of Docetaxel can be decreased when combined with 2-mercaptobenzothiazole.
2-MethoxyestradiolThe risk or severity of adverse effects can be increased when Docetaxel is combined with 2-Methoxyestradiol.
3-MethoxybenzamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with 3-Methoxybenzamide.
3,4-Dihydroxybenzoic AcidThe risk or severity of adverse effects can be increased when Docetaxel is combined with 3,4-Dihydroxybenzoic Acid.
5,10-Dideazatetrahydrofolic AcidThe risk or severity of adverse effects can be increased when Docetaxel is combined with 5,10-Dideazatetrahydrofolic Acid.
7-HydroxystaurosporineThe risk or severity of adverse effects can be increased when Docetaxel is combined with 7-Hydroxystaurosporine.
8-azaguanineThe risk or severity of adverse effects can be increased when Docetaxel is combined with 8-azaguanine.
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurineThe risk or severity of adverse effects can be increased when Docetaxel is combined with 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine.
AbirateroneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Abiraterone.
ABT-263The risk or severity of adverse effects can be increased when Docetaxel is combined with ABT-263.
AcetaminophenThe serum concentration of Docetaxel can be increased when it is combined with Acetaminophen.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Docetaxel.
AfatinibThe serum concentration of Docetaxel can be increased when it is combined with Afatinib.
AfatinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Afatinib.
AfimoxifeneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Afimoxifene.
AfliberceptThe risk or severity of adverse effects can be increased when Docetaxel is combined with Aflibercept.
AlatrofloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Alatrofloxacin.
AlbendazoleThe serum concentration of Docetaxel can be increased when it is combined with Albendazole.
AlbendazoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Albendazole.
AldesleukinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Aldesleukin.
AldosteroneThe serum concentration of Docetaxel can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Docetaxel can be increased when it is combined with Alectinib.
AlemtuzumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Alemtuzumab.
AlfentanilThe serum concentration of Docetaxel can be increased when it is combined with Alfentanil.
AlitretinoinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Alitretinoin.
Alpha-DifluoromethylornithineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Alpha-Difluoromethylornithine.
AltretamineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Altretamine.
AmantadineThe serum concentration of Docetaxel can be increased when it is combined with Amantadine.
AminoglutethimideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Aminoglutethimide.
Aminohippuric acidThe serum concentration of Docetaxel can be increased when it is combined with Aminohippuric acid.
Aminolevulinic acidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Aminolevulinic acid.
AmiodaroneThe serum concentration of Docetaxel can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Docetaxel can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Docetaxel can be increased when it is combined with Amlodipine.
AmonafideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Amonafide.
AmorolfineThe metabolism of Docetaxel can be decreased when combined with Amorolfine.
Amphotericin BThe metabolism of Docetaxel can be decreased when combined with Amphotericin B.
AmprenavirThe serum concentration of Docetaxel can be decreased when it is combined with Amprenavir.
AmrubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Amrubicin.
AmsacrineThe serum concentration of Docetaxel can be increased when it is combined with Amsacrine.
AmsacrineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Amsacrine.
AN2690The metabolism of Docetaxel can be decreased when combined with AN2690.
AnagrelideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Anagrelide.
AnastrozoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Anastrozole.
AnidulafunginThe metabolism of Docetaxel can be decreased when combined with Anidulafungin.
annamycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with annamycin.
AP 12009The risk or severity of adverse effects can be increased when Docetaxel is combined with AP 12009.
AP24534The risk or severity of adverse effects can be increased when Docetaxel is combined with AP24534.
AprepitantThe serum concentration of Docetaxel can be increased when it is combined with Aprepitant.
Arsenic trioxideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Arsenic trioxide.
ArtemetherThe metabolism of Docetaxel can be decreased when combined with Artemether.
ASA404The risk or severity of adverse effects can be increased when Docetaxel is combined with ASA404.
AsparaginaseThe risk or severity of adverse effects can be increased when Docetaxel is combined with Asparaginase.
AstemizoleThe serum concentration of Docetaxel can be increased when it is combined with Astemizole.
AT-101The risk or severity of adverse effects can be increased when Docetaxel is combined with AT-101.
AtazanavirThe serum concentration of Docetaxel can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Docetaxel can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Docetaxel can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Docetaxel can be increased when it is combined with Atorvastatin.
AxitinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Axitinib.
AzacitidineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Azacitidine.
AzathioprineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Azathioprine.
AZD2171The risk or severity of adverse effects can be increased when Docetaxel is combined with AZD2171.
Azelaic AcidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Azelaic Acid.
AzelastineThe serum concentration of Docetaxel can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Docetaxel can be increased when it is combined with Azithromycin.
Bafilomycin A1The metabolism of Docetaxel can be decreased when combined with Bafilomycin A1.
BatimastatThe risk or severity of adverse effects can be increased when Docetaxel is combined with Batimastat.
BelinostatThe risk or severity of adverse effects can be increased when Docetaxel is combined with Belinostat.
BendamustineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bendamustine.
BenzocaineThe serum concentration of Docetaxel can be increased when it is combined with Benzocaine.
Benzoic AcidThe metabolism of Docetaxel can be decreased when combined with Benzoic Acid.
BepridilThe serum concentration of Docetaxel can be increased when it is combined with Bepridil.
BesifloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Besifloxacin.
BevacizumabBevacizumab may increase the cardiotoxic activities of Docetaxel.
BevacizumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bevacizumab.
BexaroteneThe serum concentration of Docetaxel can be decreased when it is combined with Bexarotene.
BexaroteneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bexarotene.
BicalutamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bicalutamide.
BifonazoleThe metabolism of Docetaxel can be decreased when combined with Bifonazole.
BiperidenThe serum concentration of Docetaxel can be increased when it is combined with Biperiden.
BleomycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bleomycin.
BlinatumomabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Blinatumomab.
BoceprevirThe metabolism of Docetaxel can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Docetaxel can be decreased when combined with Bortezomib.
BortezomibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bortezomib.
BosentanThe serum concentration of Docetaxel can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Docetaxel can be increased when it is combined with Bosutinib.
BosutinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bosutinib.
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Brentuximab vedotin.
BromocriptineThe serum concentration of Docetaxel can be increased when it is combined with Bromocriptine.
BSI-201The risk or severity of adverse effects can be increased when Docetaxel is combined with BSI-201.
BuprenorphineThe serum concentration of Docetaxel can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Docetaxel can be increased when it is combined with Buspirone.
BusulfanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Busulfan.
ButenafineThe metabolism of Docetaxel can be decreased when combined with Butenafine.
ButoconazoleThe metabolism of Docetaxel can be decreased when combined with Butoconazole.
CabazitaxelThe serum concentration of Docetaxel can be increased when it is combined with Cabazitaxel.
CabazitaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cabazitaxel.
CabergolineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cabergoline.
CabozantinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cabozantinib.
CaffeineThe serum concentration of Docetaxel can be increased when it is combined with Caffeine.
CalcipotriolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Calcipotriol.
CamptothecinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Camptothecin.
CanagliflozinThe serum concentration of Docetaxel can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Docetaxel can be increased when it is combined with Candesartan.
CandicidinThe metabolism of Docetaxel can be decreased when combined with Candicidin.
CapecitabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Capecitabine.
CaptoprilThe serum concentration of Docetaxel can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Docetaxel can be decreased when it is combined with Carbamazepine.
CarboplatinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Carboplatin.
CarfilzomibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Carfilzomib.
CarmofurThe risk or severity of adverse effects can be increased when Docetaxel is combined with Carmofur.
CarmustineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Carmustine.
CarvedilolThe serum concentration of Docetaxel can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Docetaxel can be increased when it is combined with Caspofungin.
CatumaxomabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Catumaxomab.
CB1954The risk or severity of adverse effects can be increased when Docetaxel is combined with CB1954.
CelecoxibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Celecoxib.
CeritinibThe serum concentration of Docetaxel can be increased when it is combined with Ceritinib.
CeritinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ceritinib.
CeruleninThe metabolism of Docetaxel can be decreased when combined with Cerulenin.
CetuximabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cetuximab.
ChlorambucilThe risk or severity of adverse effects can be increased when Docetaxel is combined with Chlorambucil.
ChloroquineThe serum concentration of Docetaxel can be increased when it is combined with Chloroquine.
ChlorotrianiseneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Chlorotrianisene.
ChloroxineThe metabolism of Docetaxel can be decreased when combined with Chloroxine.
ChlorpromazineThe serum concentration of Docetaxel can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Docetaxel can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Docetaxel can be increased when it is combined with Chlorprothixene.
CholesterolThe serum concentration of Docetaxel can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Docetaxel can be decreased when it is combined with Cholic Acid.
CiclopiroxThe metabolism of Docetaxel can be decreased when combined with Ciclopirox.
CilazaprilThe serum concentration of Docetaxel can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Docetaxel can be decreased when it is combined with Cimetidine.
CinoxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cinoxacin.
CiprofloxacinThe serum concentration of Docetaxel can be increased when it is combined with Ciprofloxacin.
CiprofloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ciprofloxacin.
CisplatinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cisplatin.
CitalopramThe serum concentration of Docetaxel can be increased when it is combined with Citalopram.
CladribineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cladribine.
ClarithromycinThe serum concentration of Docetaxel can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Docetaxel can be decreased when combined with Clemastine.
ClofarabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Clofarabine.
ClofazimineThe serum concentration of Docetaxel can be increased when it is combined with Clofazimine.
ClomipramineThe serum concentration of Docetaxel can be increased when it is combined with Clomipramine.
ClotrimazoleThe metabolism of Docetaxel can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Clozapine.
CobicistatThe serum concentration of Docetaxel can be increased when it is combined with Cobicistat.
ColchicineThe serum concentration of Docetaxel can be increased when it is combined with Colchicine.
ColchicineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Colchicine.
ColforsinThe serum concentration of Docetaxel can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Docetaxel can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Docetaxel can be decreased when combined with Crizotinib.
CrizotinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Crizotinib.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Docetaxel.
CyclophosphamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cyclophosphamide.
CyclosporineThe metabolism of Docetaxel can be decreased when combined with Cyclosporine.
Cyproterone acetateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cyproterone acetate.
CytarabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cytarabine.
DabrafenibThe serum concentration of Docetaxel can be decreased when it is combined with Dabrafenib.
DabrafenibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dabrafenib.
DacarbazineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dacarbazine.
DaclatasvirThe serum concentration of Docetaxel can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Docetaxel can be increased when it is combined with Dactinomycin.
DactinomycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dactinomycin.
DaratumumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Daratumumab.
DarunavirThe metabolism of Docetaxel can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Docetaxel can be increased when it is combined with Dasatinib.
DasatinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dasatinib.
DaunorubicinThe serum concentration of Docetaxel can be decreased when it is combined with Daunorubicin.
DaunorubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Daunorubicin.
Decanoic AcidThe metabolism of Docetaxel can be decreased when combined with Decanoic Acid.
DecitabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Decitabine.
DeferasiroxThe serum concentration of Docetaxel can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Docetaxel can be decreased when combined with Delavirdine.
Denileukin diftitoxThe risk or severity of adverse effects can be increased when Docetaxel is combined with Denileukin diftitox.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Docetaxel.
DesipramineThe serum concentration of Docetaxel can be increased when it is combined with Desipramine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Docetaxel.
DesloratadineThe serum concentration of Docetaxel can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Docetaxel can be decreased when it is combined with Dexamethasone.
DexamethasoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dexamethasone.
DexrazoxaneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dexrazoxane.
DextromethorphanThe serum concentration of Docetaxel can be increased when it is combined with Dextromethorphan.
DiclofenacThe serum concentration of Docetaxel can be increased when it is combined with Diclofenac.
DienogestThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dienogest.
DiethylstilbestrolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Diethylstilbestrol.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Docetaxel.
DigoxinDigoxin may decrease the cardiotoxic activities of Docetaxel.
DihydroergotamineThe metabolism of Docetaxel can be decreased when combined with Dihydroergotamine.
DiltiazemThe metabolism of Docetaxel can be decreased when combined with Diltiazem.
DinutuximabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dinutuximab.
DipyridamoleThe serum concentration of Docetaxel can be increased when it is combined with Dipyridamole.
DoxazosinThe serum concentration of Docetaxel can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Docetaxel can be increased when it is combined with Doxepin.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Docetaxel.
DoxorubicinThe serum concentration of Docetaxel can be decreased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Docetaxel can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Docetaxel can be increased when it is combined with Dronabinol.
DronedaroneThe metabolism of Docetaxel can be decreased when combined with Dronedarone.
EcabetThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ecabet.
EconazoleThe metabolism of Docetaxel can be decreased when combined with Econazole.
efaproxiralThe risk or severity of adverse effects can be increased when Docetaxel is combined with efaproxiral.
EfavirenzThe serum concentration of Docetaxel can be decreased when it is combined with Efavirenz.
EfinaconazoleThe metabolism of Docetaxel can be decreased when combined with Efinaconazole.
EflornithineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Eflornithine.
EG009The risk or severity of adverse effects can be increased when Docetaxel is combined with EG009.
ElbasvirThe serum concentration of Docetaxel can be increased when it is combined with Elbasvir.
ElsamitrucinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Elsamitrucin.
EltrombopagThe serum concentration of Docetaxel can be increased when it is combined with Eltrombopag.
EnalaprilThe serum concentration of Docetaxel can be increased when it is combined with Enalapril.
EndostatinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Endostatin.
EnoxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Enoxacin.
EnrofloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Enrofloxacin.
EnzalutamideThe serum concentration of Docetaxel can be increased when it is combined with Enzalutamide.
EpirubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Epirubicin.
Epothilone BThe risk or severity of adverse effects can be increased when Docetaxel is combined with Epothilone B.
ErgonovineThe serum concentration of Docetaxel can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Docetaxel can be increased when it is combined with Ergotamine.
EribulinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Eribulin.
ErlotinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Erlotinib.
ErythromycinThe metabolism of Docetaxel can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Docetaxel can be decreased when it is combined with Eslicarbazepine acetate.
EstramustineThe serum concentration of Docetaxel can be increased when it is combined with Estramustine.
EstramustineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Estramustine.
EstriolThe serum concentration of Docetaxel can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Docetaxel can be decreased when it is combined with Estrone.
Ethiodized oilThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ethiodized oil.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ethyl carbamate.
EtoposideThe serum concentration of Docetaxel can be increased when it is combined with Etoposide.
EtoposideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Etoposide.
EtravirineThe serum concentration of Docetaxel can be decreased when it is combined with Etravirine.
EverolimusThe risk or severity of adverse effects can be increased when Docetaxel is combined with Everolimus.
ExemestaneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Exemestane.
exisulindThe risk or severity of adverse effects can be increased when Docetaxel is combined with exisulind.
FelodipineThe serum concentration of Docetaxel can be increased when it is combined with Felodipine.
FenretinideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fenretinide.
FentanylThe serum concentration of Docetaxel can be increased when it is combined with Fentanyl.
FexofenadineThe serum concentration of Docetaxel can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Docetaxel can be increased when it is combined with Fidaxomicin.
FingolimodDocetaxel may increase the immunosuppressive activities of Fingolimod.
FlavopiridolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Flavopiridol.
FleroxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fleroxacin.
FloxuridineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Floxuridine.
FluconazoleThe metabolism of Docetaxel can be decreased when combined with Fluconazole.
FlucytosineThe metabolism of Docetaxel can be decreased when combined with Flucytosine.
FludarabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fludarabine.
FlumequineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Flumequine.
FluorouracilThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fluorouracil.
FluoxetineThe serum concentration of Docetaxel can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Docetaxel can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Docetaxel can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Docetaxel can be increased when it is combined with Flurazepam.
FlutamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Flutamide.
FluvoxamineThe metabolism of Docetaxel can be decreased when combined with Fluvoxamine.
FormestaneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Formestane.
FormycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Formycin.
FosamprenavirThe metabolism of Docetaxel can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Docetaxel can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Docetaxel can be increased when combined with Fosphenytoin.
FotemustineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fotemustine.
FulvestrantThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fulvestrant.
FumagillinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fumagillin.
Fusidic AcidThe serum concentration of Docetaxel can be increased when it is combined with Fusidic Acid.
Gallium nitrateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gallium nitrate.
GarenoxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Garenoxacin.
GatifloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gatifloxacin.
GefitinibThe serum concentration of Docetaxel can be increased when it is combined with Gefitinib.
GefitinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gefitinib.
GeldanamycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Geldanamycin.
GemcitabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gemcitabine.
GemifloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gemifloxacin.
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gemtuzumab ozogamicin.
GenisteinThe serum concentration of Docetaxel can be increased when it is combined with Genistein.
GenisteinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Genistein.
Ginsenoside CThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ginsenoside C.
GlyburideThe serum concentration of Docetaxel can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Docetaxel can be increased when it is combined with Glycerol.
GlyphosateThe metabolism of Docetaxel can be decreased when combined with Glyphosate.
GoserelinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Goserelin.
Gramicidin DThe serum concentration of Docetaxel can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Docetaxel can be increased when it is combined with Grepafloxacin.
GrepafloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Grepafloxacin.
GriseofulvinThe metabolism of Docetaxel can be decreased when combined with Griseofulvin.
HadacidinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Hadacidin.
HalofuginoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Halofuginone.
HaloperidolThe serum concentration of Docetaxel can be increased when it is combined with Haloperidol.
HaloproginThe metabolism of Docetaxel can be decreased when combined with Haloprogin.
HexestrolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Hexestrol.
HexetidineThe metabolism of Docetaxel can be decreased when combined with Hexetidine.
HydrocortisoneThe serum concentration of Docetaxel can be increased when it is combined with Hydrocortisone.
Hydroxyprogesterone caproateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Hydroxyprogesterone caproate.
HydroxyureaThe risk or severity of adverse effects can be increased when Docetaxel is combined with Hydroxyurea.
IbrutinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ibrutinib.
IdarubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Idarubicin.
IdelalisibThe serum concentration of Docetaxel can be increased when it is combined with Idelalisib.
IdelalisibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Idelalisib.
IfosfamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ifosfamide.
ImatinibThe metabolism of Docetaxel can be decreased when combined with Imatinib.
ImatinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Imatinib.
ImipramineThe serum concentration of Docetaxel can be increased when it is combined with Imipramine.
ImiquimodThe risk or severity of adverse effects can be increased when Docetaxel is combined with Imiquimod.
IndinavirThe serum concentration of Docetaxel can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Docetaxel can be increased when it is combined with Indomethacin.
Interferon beta-1aThe risk or severity of adverse effects can be increased when Docetaxel is combined with Interferon beta-1a.
IobenguaneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Iobenguane.
IpilimumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ipilimumab.
IrinotecanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Irinotecan.
IsavuconazoniumThe metabolism of Docetaxel can be decreased when combined with Isavuconazonium.
IsoconazoleThe metabolism of Docetaxel can be decreased when combined with Isoconazole.
IsradipineThe metabolism of Docetaxel can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Docetaxel can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Docetaxel can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Docetaxel can be increased when it is combined with Ivermectin.
IxabepiloneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ixabepilone.
IxazomibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ixazomib.
KetamineThe serum concentration of Docetaxel can be increased when it is combined with Ketamine.
KetoconazoleThe serum concentration of Docetaxel can be increased when it is combined with Ketoconazole.
KOS-1584The risk or severity of adverse effects can be increased when Docetaxel is combined with KOS-1584.
L-alanosineThe risk or severity of adverse effects can be increased when Docetaxel is combined with L-alanosine.
LanreotideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lanreotide.
LansoprazoleThe serum concentration of Docetaxel can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Docetaxel can be increased when it is combined with Lapatinib.
LapatinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lapatinib.
LeflunomideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Leflunomide.
LenalidomideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lenalidomide.
LenvatinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lenvatinib.
LetrozoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Letrozole.
LeuprolideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Leuprolide.
LevofloxacinThe serum concentration of Docetaxel can be increased when it is combined with Levofloxacin.
LevofloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Levofloxacin.
LevothyroxineThe serum concentration of Docetaxel can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Docetaxel can be increased when it is combined with Lidocaine.
LiothyronineThe serum concentration of Docetaxel can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Docetaxel can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Docetaxel can be increased when it is combined with Lisinopril.
LomefloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lomefloxacin.
LomitapideThe serum concentration of Docetaxel can be increased when it is combined with Lomitapide.
LomustineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lomustine.
LonidamineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lonidamine.
LoperamideThe serum concentration of Docetaxel can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Docetaxel can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Docetaxel can be increased when it is combined with Loratadine.
LosartanThe serum concentration of Docetaxel can be increased when it is combined with Losartan.
LovastatinThe metabolism of Docetaxel can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Docetaxel can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Docetaxel can be decreased when it is combined with Lumacaftor.
LycopeneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lycopene.
MaprotilineThe serum concentration of Docetaxel can be increased when it is combined with Maprotiline.
MasitinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Masitinib.
MasoprocolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Masoprocol.
MaxacalcitolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Maxacalcitol.
MDX-1106The risk or severity of adverse effects can be increased when Docetaxel is combined with MDX-1106.
MebendazoleThe serum concentration of Docetaxel can be increased when it is combined with Mebendazole.
MebendazoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mebendazole.
MechlorethamineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mechlorethamine.
MedrogestoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Medrogestone.
Medroxyprogesterone acetateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Medroxyprogesterone acetate.
MefloquineThe serum concentration of Docetaxel can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Docetaxel can be increased when it is combined with Megestrol acetate.
Megestrol acetateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Megestrol acetate.
MelphalanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Melphalan.
MeprobamateThe serum concentration of Docetaxel can be increased when it is combined with Meprobamate.
MequinolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mequinol.
MercaptopurineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mercaptopurine.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Docetaxel.
MethadoneThe serum concentration of Docetaxel can be increased when it is combined with Methadone.
MethotrexateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Methotrexate.
Methyl aminolevulinateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Methyl aminolevulinate.
MethylprednisoloneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Methylprednisolone.
MethyltestosteroneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Methyltestosterone.
MetoprololThe serum concentration of Docetaxel can be increased when it is combined with Metoprolol.
MevastatinThe metabolism of Docetaxel can be decreased when combined with Mevastatin.
MGI-114The risk or severity of adverse effects can be increased when Docetaxel is combined with MGI-114.
MibefradilThe serum concentration of Docetaxel can be increased when it is combined with Mibefradil.
MicafunginThe metabolism of Docetaxel can be decreased when combined with Micafungin.
MiconazoleThe serum concentration of Docetaxel can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Docetaxel can be decreased when it is combined with Midazolam.
MidostaurinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Midostaurin.
MifepristoneThe metabolism of Docetaxel can be decreased when combined with Mifepristone.
MiltefosineThe metabolism of Docetaxel can be decreased when combined with Miltefosine.
MiltefosineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Miltefosine.
MitomycinThe serum concentration of Docetaxel can be increased when it is combined with Mitomycin.
MitomycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mitomycin.
MitotaneThe serum concentration of Docetaxel can be decreased when it is combined with Mitotane.
MitotaneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mitotane.
MitoxantroneThe serum concentration of Docetaxel can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mitoxantrone.
ModafinilThe serum concentration of Docetaxel can be decreased when it is combined with Modafinil.
MonensinThe metabolism of Docetaxel can be decreased when combined with Monensin.
MorphineThe serum concentration of Docetaxel can be increased when it is combined with Morphine.
motexafin gadoliniumThe risk or severity of adverse effects can be increased when Docetaxel is combined with motexafin gadolinium.
MoxifloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Moxifloxacin.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mycophenolic acid.
MyxothiazolThe metabolism of Docetaxel can be decreased when combined with Myxothiazol.
NafcillinThe serum concentration of Docetaxel can be decreased when it is combined with Nafcillin.
NaftifineThe metabolism of Docetaxel can be decreased when combined with Naftifine.
Nalidixic AcidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nalidixic Acid.
NaltrexoneThe serum concentration of Docetaxel can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Docetaxel can be increased when it is combined with Naringenin.
NatalizumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Natalizumab.
NatamycinThe metabolism of Docetaxel can be decreased when combined with Natamycin.
NecitumumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Necitumumab.
NefazodoneThe serum concentration of Docetaxel can be decreased when it is combined with Nefazodone.
NelarabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nelarabine.
NelfinavirThe serum concentration of Docetaxel can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Docetaxel can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Docetaxel can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Docetaxel can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Docetaxel can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Docetaxel can be decreased when it is combined with Nifedipine.
NiguldipineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Niguldipine.
NilotinibThe metabolism of Docetaxel can be decreased when combined with Nilotinib.
NilotinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nilotinib.
NilutamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nilutamide.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Docetaxel.
NisoldipineThe serum concentration of Docetaxel can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Docetaxel can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Docetaxel can be increased when it is combined with Nitrendipine.
NitroxolineThe metabolism of Docetaxel can be decreased when combined with Nitroxoline.
NivolumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nivolumab.
nocodazoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with nocodazole.
NorethisteroneThe serum concentration of Docetaxel can be decreased when it is combined with Norethisterone.
NorfloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Norfloxacin.
NystatinThe metabolism of Docetaxel can be decreased when combined with Nystatin.
ObinutuzumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Obinutuzumab.
OctreotideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Octreotide.
OfatumumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ofatumumab.
OfloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ofloxacin.
OlaparibThe metabolism of Docetaxel can be decreased when combined with Olaparib.
OlaparibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Olaparib.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Omacetaxine mepesuccinate.
OmeprazoleThe serum concentration of Docetaxel can be increased when it is combined with Omeprazole.
OprelvekinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Oprelvekin.
OsimertinibThe serum concentration of Docetaxel can be increased when it is combined with Osimertinib.
OsimertinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Osimertinib.
OuabainOuabain may decrease the cardiotoxic activities of Docetaxel.
OxaliplatinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Oxaliplatin.
OxiconazoleThe metabolism of Docetaxel can be decreased when combined with Oxiconazole.
P-NitrophenolThe serum concentration of Docetaxel can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Docetaxel can be increased when it is combined with Paclitaxel.
PaclitaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Paclitaxel.
pafuramidineThe metabolism of Docetaxel can be decreased when combined with pafuramidine.
PalbociclibThe serum concentration of Docetaxel can be increased when it is combined with Palbociclib.
PalbociclibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Palbociclib.
PalifosfamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Palifosfamide.
Palmitic AcidThe serum concentration of Docetaxel can be increased when it is combined with Palmitic Acid.
PamidronateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pamidronate.
PanitumumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Panitumumab.
PanobinostatThe risk or severity of adverse effects can be increased when Docetaxel is combined with Panobinostat.
PantoprazoleThe serum concentration of Docetaxel can be increased when it is combined with Pantoprazole.
ParoxetineThe serum concentration of Docetaxel can be increased when it is combined with Paroxetine.
PazopanibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pazopanib.
PefloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pefloxacin.
PegaspargaseThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pegaspargase.
PembrolizumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pembrolizumab.
PemetrexedThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pemetrexed.
PentamidineThe metabolism of Docetaxel can be decreased when combined with Pentamidine.
PentobarbitalThe metabolism of Docetaxel can be increased when combined with Pentobarbital.
PentostatinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pentostatin.
PerindoprilThe serum concentration of Docetaxel can be increased when it is combined with Perindopril.
PertuzumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pertuzumab.
PhenobarbitalThe serum concentration of Docetaxel can be decreased when it is combined with Phenobarbital.
Phenylacetic acidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Phenylacetic acid.
PhenytoinThe metabolism of Docetaxel can be increased when combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Docetaxel.
PimozideThe serum concentration of Docetaxel can be increased when it is combined with Pimozide.
PipobromanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pipobroman.
PirfenidoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pirfenidone.
PirlindoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pirlindole.
PixantroneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pixantrone.
Platelet Activating FactorThe serum concentration of Docetaxel can be decreased when it is combined with Platelet Activating Factor.
PlicamycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Plicamycin.
PodofiloxThe risk or severity of adverse effects can be increased when Docetaxel is combined with Podofilox.
PodophyllinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Podophyllin.
polyacrylic acidThe risk or severity of adverse effects can be increased when Docetaxel is combined with polyacrylic acid.
PomalidomideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pomalidomide.
PonatinibThe serum concentration of Docetaxel can be increased when it is combined with Ponatinib.
PonatinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ponatinib.
PorfimerThe risk or severity of adverse effects can be increased when Docetaxel is combined with Porfimer.
porfiromycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with porfiromycin.
PosaconazoleThe serum concentration of Docetaxel can be increased when it is combined with Posaconazole.
PralatrexateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pralatrexate.
PravastatinThe serum concentration of Docetaxel can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Docetaxel can be increased when it is combined with Prazosin.
PrednisoloneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Prednisolone.
PrednisoneThe serum concentration of Docetaxel can be increased when it is combined with Prednisone.
PrednisoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Prednisone.
PrimidoneThe metabolism of Docetaxel can be increased when combined with Primidone.
ProbenecidThe serum concentration of Docetaxel can be increased when it is combined with Probenecid.
ProcarbazineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Procarbazine.
ProgesteroneThe serum concentration of Docetaxel can be decreased when it is combined with Progesterone.
PromethazineThe serum concentration of Docetaxel can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Docetaxel can be increased when it is combined with Propafenone.
PropranololThe serum concentration of Docetaxel can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Docetaxel can be increased when it is combined with Protriptyline.
Purine RibosideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Purine Riboside.
PuromycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Puromycin.
QuercetinThe serum concentration of Docetaxel can be increased when it is combined with Quercetin.
QuinacrineThe serum concentration of Docetaxel can be increased when it is combined with Quinacrine.
QuinacrineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Quinacrine.
QuinidineThe serum concentration of Docetaxel can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Docetaxel can be increased when it is combined with Quinine.
Rabies vaccineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Rabies vaccine.
RadicicolThe metabolism of Docetaxel can be decreased when combined with Radicicol.
Radium Ra 223 DichlorideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Radium Ra 223 Dichloride.
RaltitrexedThe risk or severity of adverse effects can be increased when Docetaxel is combined with Raltitrexed.
RamucirumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ramucirumab.
RanibizumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ranibizumab.
RanitidineThe serum concentration of Docetaxel can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Docetaxel can be increased when it is combined with Ranolazine.
RanpirnaseThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ranpirnase.
ReboxetineThe serum concentration of Docetaxel can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Docetaxel can be increased when it is combined with Regorafenib.
RegorafenibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Regorafenib.
ReserpineThe serum concentration of Docetaxel can be decreased when it is combined with Reserpine.
ResveratrolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Resveratrol.
Rhodamine 6GThe risk or severity of adverse effects can be increased when Docetaxel is combined with Rhodamine 6G.
RifabutinThe metabolism of Docetaxel can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Docetaxel can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Docetaxel can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Docetaxel can be increased when it is combined with Rilpivirine.
RitonavirThe serum concentration of Docetaxel can be decreased when it is combined with Ritonavir.
RituximabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Rituximab.
RoflumilastRoflumilast may increase the immunosuppressive activities of Docetaxel.
RolapitantThe serum concentration of Docetaxel can be increased when it is combined with Rolapitant.
RomidepsinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Romidepsin.
RomiplostimThe risk or severity of adverse effects can be increased when Docetaxel is combined with Romiplostim.
RoquinimexThe risk or severity of adverse effects can be increased when Docetaxel is combined with Roquinimex.
RubitecanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Rubitecan.
RuxolitinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ruxolitinib.
Salicylhydroxamic AcidThe metabolism of Docetaxel can be decreased when combined with Salicylhydroxamic Acid.
Salicylic acidThe metabolism of Docetaxel can be decreased when combined with Salicylic acid.
SaquinavirThe serum concentration of Docetaxel can be decreased when it is combined with Saquinavir.
SatraplatinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Satraplatin.
ScopolamineThe serum concentration of Docetaxel can be increased when it is combined with Scopolamine.
SelegilineThe serum concentration of Docetaxel can be increased when it is combined with Selegiline.
SeliciclibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Seliciclib.
SemaxanibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Semaxanib.
SeocalcitolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Seocalcitol.
SertaconazoleThe metabolism of Docetaxel can be decreased when combined with Sertaconazole.
SertralineThe serum concentration of Docetaxel can be increased when it is combined with Sertraline.
SildenafilThe metabolism of Docetaxel can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Docetaxel can be decreased when it is combined with Siltuximab.
SiltuximabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Siltuximab.
SimeprevirThe serum concentration of Docetaxel can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Docetaxel can be increased when it is combined with Simvastatin.
SinefunginThe metabolism of Docetaxel can be decreased when combined with Sinefungin.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Docetaxel.
SirolimusThe serum concentration of Docetaxel can be decreased when it is combined with Sirolimus.
SirolimusThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sirolimus.
SonidegibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sonidegib.
SorafenibThe serum concentration of Docetaxel can be increased when it is combined with Sorafenib.
SorafenibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sorafenib.
SparfloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sparfloxacin.
Sparfosic acidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sparfosic acid.
SparsomycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sparsomycin.
SpironolactoneThe serum concentration of Docetaxel can be increased when it is combined with Spironolactone.
squalamineThe risk or severity of adverse effects can be increased when Docetaxel is combined with squalamine.
SRT501The risk or severity of adverse effects can be increased when Docetaxel is combined with SRT501.
St. John's WortThe serum concentration of Docetaxel can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Docetaxel can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Docetaxel can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Docetaxel can be decreased when it is combined with Streptozocin.
StreptozocinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Streptozocin.
SulconazoleThe metabolism of Docetaxel can be decreased when combined with Sulconazole.
SulfinpyrazoneThe serum concentration of Docetaxel can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Docetaxel can be decreased when combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sulindac.
SumatriptanThe serum concentration of Docetaxel can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Docetaxel can be increased when it is combined with Sunitinib.
SunitinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sunitinib.
SuraminThe risk or severity of adverse effects can be increased when Docetaxel is combined with Suramin.
SwainsonineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Swainsonine.
TacrineThe serum concentration of Docetaxel can be increased when it is combined with Tacrine.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Docetaxel.
TamoxifenThe serum concentration of Docetaxel can be decreased when it is combined with Tamoxifen.
TamoxifenThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tamoxifen.
Taurocholic AcidThe serum concentration of Docetaxel can be increased when it is combined with Taurocholic Acid.
TavaboroleThe metabolism of Docetaxel can be decreased when combined with Tavaborole.
TegafurThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tegafur.
TelaprevirThe metabolism of Docetaxel can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Docetaxel can be decreased when combined with Telithromycin.
TelmisartanThe serum concentration of Docetaxel can be increased when it is combined with Telmisartan.
TemafloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Temafloxacin.
TemozolomideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Temozolomide.
TemsirolimusThe serum concentration of Docetaxel can be increased when it is combined with Temsirolimus.
TemsirolimusThe risk or severity of adverse effects can be increased when Docetaxel is combined with Temsirolimus.
TeniposideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Teniposide.
TerazosinThe serum concentration of Docetaxel can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Docetaxel can be decreased when combined with Terbinafine.
TerconazoleThe metabolism of Docetaxel can be decreased when combined with Terconazole.
TerfenadineThe serum concentration of Docetaxel can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Docetaxel can be increased when it is combined with Teriflunomide.
TesmilifeneThe serum concentration of Docetaxel can be decreased when it is combined with Tesmilifene.
TestolactoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Testolactone.
TestosteroneThe serum concentration of Docetaxel can be increased when it is combined with Testosterone.
TetrathiomolybdateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tetrathiomolybdate.
TezacitabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tezacitabine.
ThalidomideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Thalidomide.
ThiotepaThe risk or severity of adverse effects can be increased when Docetaxel is combined with Thiotepa.
ThymalfasinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Thymalfasin.
ThymolThe metabolism of Docetaxel can be decreased when combined with Thymol.
TiboloneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tibolone.
TicagrelorThe serum concentration of Docetaxel can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Docetaxel can be decreased when combined with Ticlopidine.
TioconazoleThe metabolism of Docetaxel can be decreased when combined with Tioconazole.
TioguanineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tioguanine.
TipifarnibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tipifarnib.
TirapazamineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tirapazamine.
TocilizumabThe serum concentration of Docetaxel can be decreased when it is combined with Tocilizumab.
TofacitinibDocetaxel may increase the immunosuppressive activities of Tofacitinib.
TolnaftateThe metabolism of Docetaxel can be decreased when combined with Tolnaftate.
TolvaptanThe serum concentration of Docetaxel can be increased when it is combined with Tolvaptan.
TopotecanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Topotecan.
ToremifeneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Toremifene.
TositumomabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tositumomab.
TrabectedinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trabectedin.
TrametinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trametinib.
TrastuzumabTrastuzumab may increase the neutropenic activities of Docetaxel.
TrastuzumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trastuzumab.
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trastuzumab emtansine.
TrazodoneThe serum concentration of Docetaxel can be decreased when it is combined with Trazodone.
TretinoinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tretinoin.
TrifluoperazineThe serum concentration of Docetaxel can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Docetaxel can be increased when it is combined with Triflupromazine.
TrifluridineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trifluridine.
TrilostaneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trilostane.
TrimethoprimThe serum concentration of Docetaxel can be decreased when it is combined with Trimethoprim.
TrimetrexateThe metabolism of Docetaxel can be decreased when combined with Trimetrexate.
TrimetrexateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trimetrexate.
TrimipramineThe serum concentration of Docetaxel can be increased when it is combined with Trimipramine.
TriptorelinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Triptorelin.
TroleandomycinThe serum concentration of Docetaxel can be increased when it is combined with Troleandomycin.
TrovafloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trovafloxacin.
TroxacitabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Troxacitabine.
TTNPBThe risk or severity of adverse effects can be increased when Docetaxel is combined with TTNPB.
TubercidinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tubercidin.
UbenimexThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ubenimex.
Uracil mustardThe risk or severity of adverse effects can be increased when Docetaxel is combined with Uracil mustard.
ValrubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Valrubicin.
VandetanibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vandetanib.
VapreotideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vapreotide.
VeliparibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Veliparib.
VemurafenibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vemurafenib.
VenlafaxineThe metabolism of Docetaxel can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Docetaxel can be decreased when combined with Verapamil.
VerteporfinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Verteporfin.
VinblastineThe serum concentration of Docetaxel can be decreased when it is combined with Vinblastine.
VinblastineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vinblastine.
VincristineThe serum concentration of Docetaxel can be decreased when it is combined with Vincristine.
VincristineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vincristine.
VindesineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vindesine.
VinorelbineThe serum concentration of Docetaxel can be increased when it is combined with Vinorelbine.
VinorelbineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vinorelbine.
VismodegibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vismodegib.
Vitamin AThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vitamin A.
VoriconazoleThe metabolism of Docetaxel can be decreased when combined with Voriconazole.
VorinostatThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vorinostat.
ZimelidineThe serum concentration of Docetaxel can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Docetaxel can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Structural constituent of cytoskeleton
Specific Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain (By similarity).
Gene Name:
TUBB1
Uniprot ID:
Q9H4B7
Molecular Weight:
50326.56 Da
References
  1. Gligorov J, Lotz JP: Preclinical pharmacology of the taxanes: implications of the differences. Oncologist. 2004;9 Suppl 2:3-8. [PubMed:15161985 ]
  2. Matesanz R, Barasoain I, Yang CG, Wang L, Li X, de Ines C, Coderch C, Gago F, Barbero JJ, Andreu JM, Fang WS, Diaz JF: Optimization of taxane binding to microtubules: binding affinity dissection and incremental construction of a high-affinity analog of paclitaxel. Chem Biol. 2008 Jun;15(6):573-85. doi: 10.1016/j.chembiol.2008.05.008. [PubMed:18559268 ]
  3. Snyder JP, Nettles JH, Cornett B, Downing KH, Nogales E: The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density. Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5312-6. Epub 2001 Apr 17. [PubMed:11309480 ]
  4. Belani CP, Eckardt J: Development of docetaxel in advanced non-small-cell lung cancer. Lung Cancer. 2004 Dec;46 Suppl 2:S3-11. [PubMed:15698529 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Ubiquitin protein ligase binding
Specific Function:
Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating f...
Gene Name:
BCL2
Uniprot ID:
P10415
Molecular Weight:
26265.66 Da
References
  1. Gligorov J, Lotz JP: Preclinical pharmacology of the taxanes: implications of the differences. Oncologist. 2004;9 Suppl 2:3-8. [PubMed:15161985 ]
  2. Marshall J, Chen H, Yang D, Figueira M, Bouker KB, Ling Y, Lippman M, Frankel SR, Hayes DF: A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol. 2004 Aug;15(8):1274-83. [PubMed:15277270 ]
  3. Inoue Y, Gika M, Abiko T, Oyama T, Saitoh Y, Yamazaki H, Nakamura M, Abe Y, Kawamura M, Kobayashi K: Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer. Oncol Rep. 2005 Feb;13(2):259-64. [PubMed:15643508 ]
  4. Petrylak DP: Chemotherapy for androgen-independent prostate cancer. World J Urol. 2005 Feb;23(1):10-3. Epub 2005 Feb 1. [PubMed:15685445 ]
  5. Miyoshi Y, Uemura H, Kubota Y: [Treatment of androgen-independent hormone refractory prostate cancer using docetaxel]. Nihon Rinsho. 2005 Feb;63(2):298-302. [PubMed:15714982 ]
  6. Magi-Galluzzi C, Zhou M, Reuther AM, Dreicer R, Klein EA: Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer. 2007 Sep 15;110(6):1248-54. [PubMed:17674353 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Structural molecule activity
Specific Function:
The exact function of MAP2 is unknown but MAPs may stabilize the microtubules against depolymerization. They also seem to have a stiffening effect on microtubules.
Gene Name:
MAP2
Uniprot ID:
P11137
Molecular Weight:
199524.51 Da
References
  1. McGrogan BT, Gilmartin B, Carney DN, McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008 Apr;1785(2):96-132. Epub 2007 Nov 12. [PubMed:18068131 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Structural molecule activity
Specific Function:
Non-neuronal microtubule-associated protein. Promotes microtubule assembly.
Gene Name:
MAP4
Uniprot ID:
P27816
Molecular Weight:
121003.805 Da
References
  1. McGrogan BT, Gilmartin B, Carney DN, McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008 Apr;1785(2):96-132. Epub 2007 Nov 12. [PubMed:18068131 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Structural constituent of cytoskeleton
Specific Function:
Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the ce...
Gene Name:
MAPT
Uniprot ID:
P10636
Molecular Weight:
78927.025 Da
References
  1. McGrogan BT, Gilmartin B, Carney DN, McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008 Apr;1785(2):96-132. Epub 2007 Nov 12. [PubMed:18068131 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Zinc ion binding
Specific Function:
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism and secretion of potentially harmful xenobiotics, drugs and endogenous compounds. Activated by the antibiotic rifampicin and various plant metabolites, such as hyperforin, guggulipid, colupulone, and is...
Gene Name:
NR1I2
Uniprot ID:
O75469
Molecular Weight:
49761.245 Da
References
  1. Ikezoe T, Hisatake Y, Takeuchi T, Ohtsuki Y, Yang Y, Said JW, Taguchi H, Koeffler HP: HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res. 2004 Oct 15;64(20):7426-31. [PubMed:15492266 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo IJ, Scherman D: Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol. 1994 Oct 7;48(7):1528-30. [PubMed:7945455 ]
  2. Shirakawa K, Takara K, Tanigawara Y, Aoyama N, Kasuga M, Komada F, Sakaeda T, Okumura K: Interaction of docetaxel ("Taxotere") with human P-glycoprotein. Jpn J Cancer Res. 1999 Dec;90(12):1380-6. [PubMed:10665657 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name:
ABCC10
Uniprot ID:
Q5T3U5
Molecular Weight:
161627.375 Da
References
  1. Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, Kruh GD: Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res. 2009 Jan 1;69(1):178-84. doi: 10.1158/0008-5472.CAN-08-1420. [PubMed:19118001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, Wolff AC, Carducci MA, Sparreboom A: Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther. 2009 Feb;85(2):155-63. doi: 10.1038/clpt.2008.95. Epub 2008 May 28. [PubMed:18509327 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Kobayashi Y, Ohshiro N, Sakai R, Ohbayashi M, Kohyama N, Yamamoto T: Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8. [PubMed:15901346 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G: Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest. 2002 Nov;110(9):1309-18. [PubMed:12417570 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G: Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest. 2002 Nov;110(9):1309-18. [PubMed:12417570 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G: Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest. 2002 Nov;110(9):1309-18. [PubMed:12417570 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 25, 2016 03:14